A B S T R A C T This study examines the ontogenesis of somatomedin and insulin receptors in man. Particulate plasma membranes were prepared by ultracentrifugation from various tissues removed from fetuses after abortion and classified as <17, 17-25, and >25 cm in length. The binding of iodinated insulinlike growth factors 1 (IGF-1) and 2 (IGF-2), somatomedin A (SMA), multiplication-stimulating activity (MSA), and insulin was examined at the different ages.
INTRODUCTION
The first stage in the action of polypeptide hormones like insulin and the somatomedins is their binding to specific receptor sites on the plasma membrane of their target cells. The existence of such receptors may be used to indicate the targets for hormone action. Several lines of evidence indicate that fetal growth may be regulated by somatomedins and insulin (for review see 1, 2) . Accordingly, somatomedin receptors have been found in the fetal pig (3), rat (4) , and sheep (5) . In both pig lung (3) and rat brain (4) , the concentration of somatomedin receptors is greater in fetal as compared with adult tissue. In man, Rosenfeld et al. (6) reported that the number of somatomedin receptor sites on mononuclear cells was greater in neonates than in adults. Insulin receptors have been reported in fetal pig (3) , rat (7, 8) , rabbit, and guinea pig (8) . In man, insulin binding to mononuclear cells is higher in newborns than in adults (9) and in preterm as compared with term infants (10) .
It has been suggested that somatomedins may regulate the early proliferative phase of fetal growth, whereas insulin may influence later hypertrophic growth (11) . This study examines the ontogenesis of both somatomedin and insulin receptors in man and relates this to available knowledge concerning the phase of cellular growth in the different organs.
METHODS
Reagents and hormone preparations. Purified insulinlike growth factor 1 (IGF-1)' and 2 (IGF-2) as well as a partially 'Abbreviations used in this paper: IGF-1 and IGF-2, insulinlike growth factor 1 and 2; MSA, multiplication-stimulating activity; SMA, somatomedin A. purified preparation of IGF, specific activity 12.5% of pure IGF, were kindly provided by R. Humbel. Purified somatomedin A (SMA) and a partially purified preparation of SMA, specific activity 10% of pure SMA, were provided by L. Fryklund. Multiplication-stimulating activity (MSA) was kindly provided by S. P. Nissley and M. M. Rechler. Sephadex G-75 MSA II, containing four closely related polypeptides (12) was used for displacement studies whereas MSA-II-1, prepared from MSA II by preparative-scale disc acrylamide gel electrophoresis (12) , was used for iodination. MSA obtained from Collaborative Research Inc., Waltham, MA (MSA-CR) was also used for displacement studies. Porcine insulin (25 IU/mg) and proinsulin were supplied by the Nordic Insulin Laboratories, Niels Steensenvej, 1-DK2820 Gentofte, Denmark. The growth hormone used was Crescormon (4 U/mg), KabiVitrum AB, S-1128 Stockholm. Hormones were labeled by the lactoperoxidase method as described earlier (13) . The iodinated IGF-1, IGF-2, MSA, SMA, and insulin were purified on carboxymethylcellulose on a pH gradient in ammonium acetate buffer (0.1 M/liter) (13) .
Human fetal tissue. Fetuses were collected with the Ethical Committee's permission. Immediately after legal prostaglandin abortion fetuses were measured and stored in sterile saline at 40C. The youngest fetuses examined were 10 cm in length. Fetuses were classified into three age groups according to length: (a) <17 cm (n = 20); (b) [17] [18] [19] [20] [21] [22] [23] [24] [25] (14) . No significant change in binding was observed when organs were removed within 12 h after abortion. In the three fetuses examined, the total specific binding of`ssI-SMA to brain plasma membranes was not affected according to whether the brain tissue was removed immediately (mean±SEM: 5.6±0.2%) or 12 h after abortion (5.6±0.1%). Particulate plasma membranes were prepared from the different organs by ultracentrifugation as described earlier (15) . Plasma membranes were pooled according to the various age groups, the protein content determined by the method of Lowry et al. (16) The number and affinity of receptor sites were calculated by Scatchard analysis (17) using the MLAB program provided by National Institues of Health in a Dec 10 computer system. The results were drawn by computer using the MLAB program.
RESULTS
In a screening procedure all fetal organs examined, i.e., liver, brain, heart, kidney, lung, and adrenals were found to bind iodinated somatomedins and insulin.
Because of the limited availability of hormones in In liver membranes examined at four stages throughout fetal development the highest specific binding is found with 1251-labeled insulin and IGF-2 even though the latter displays high nonspecific binding. 1251-Labeled IGF-1, MSA, and SMA show far less specific binding to fetal liver membranes than IGF-2 ( Table I ). Fig. 1 shows the displacement curves of bound "25I-insulin and '25I-IGF-2 by increasing concentrations of insulin, IGF-1, IGF-2, and impure IGF. Insulin did not cross-react in the IGF-2 receptor. In contrast, impure IGF competed with insulin for its receptor and was -1,000 times less potent than insulin in displacing '25I-insulin from the liver membrane. Competitive binding by other somatomedins was examined in the 17-25-cm group (data not shown). The relative potencies compared with insulin in displacing '251-insulin were IGF-2-1:100; IGF-1-1:300; MSA-CR-1:300. Partially purified SMA (10%) was nonreactive at concentrations up to 3 ,ug/ml. The relative potencies compared with IGF-2 in displacing '25I-IGF-2 were IGF-1-1:10; MSA-CR-1:10; SMA (10%) 1 branes at different fetal ages is given in Fig. 2 . A curvilinear plot is observed at each fetal stage indicating the presence of at least two binding sites or negative co-operativity. Since resolution of these alternatives is beyond the scope of this paper, the presence of two receptor sites was assumed and the calculated affinity and concentration of high-and low-affinity insulin binding sites is given in Table II . The increase in specific binding at fetal size >25 cm is mainly attributed to the increase in the concentration of binding sites with gestational age. A change in the characteristics of the insulin receptor is suggested in the youngest fetal group by the alteration in affinity of both the high-and low-affinity insulin binding sites.
In contrast to insulin, Scatchard Ontogenesis of Somatomedin and Insulin Receptors in the Human Fetus three age groups is given in Fig. 3 (Tables II and III ). An interesting change in the pattern of cross-reaction when IGF-1 is used as label is observed on the brain plasma membrane during development (Fig. 3) . In the youngest fetal group (<17 cm in length), 1251.. IGF-1 is preferentially displaced by IGF-2 whereas in the 17-25-cm fetal group, IGF-1 and IGF-2 are equipotent, and in the oldest fetal group (>25 cm), IGF-1 is more potent than IGF-2. This change in specificity confirmed by repeat experiment, cannot be attributed to the ligand, since when tested on human term placenta membrane, IGF-1 was threefold more potent than IGF-2 in displacing '25I-IGF-1. Moreover in the >25-cm fetal group, IGF-1 again preferentially displaces '251-IGF-I from the brain membrane. These results suggest alterations in the characteristics of the IGF-1 receptor during development, which is also apparent in the Scatchard plots for IGF-1 binding to human fetal brain plasma membrane (Fig. 4) 6 shows the cross-reaction of IGF-1, IGF-2, SMA, MSA and insulin when each hormone is used as the ligand.
The highest total specific binding was found with 1251-IGF-1 (13.3%) followed by 1251-IGF-2 (5.9%), '251-SMA (5.7%), '251-MSA (3.4%), and '251-insulin (2.5%). At this age, regardless of which '251-somatomedin is used as the ligand, it is best displaced by IGF-1 and IGF-2. When 1251-IGF-1, 1251-SMA, or '25I-MSA were used the pattern of cross-reaction was identical. IGF-1 and IGF-2 were equipotent. SMA and MSA were -10-fold less potent than IGF-1 and IGF-2. Since the partially purified SMA (10%) was equipotent with SMA (data not shown), this preparation must contain hormones additional to SMA that cross-react in the brain receptor. Insulin and proinsulin (data not shown) were 100 and 1,000 times respectively less potent than IGF-1. Other hormones, such as growth hormone and prolactin, and growth factors such as nerve growth factor, fibroblast growth factor, and epidermal growth factor did not cross-react in the human fetal brain somatomedin receptor. With IGF-2 as the labeled hormone the pattern of cross-reaction is quite different. None of the tested hormones showed displacement curves parallel with that for IGF-2. The order of potency was discrepant from other somatomedins and insulin only caused a 50% inhibition of the bound '251-IGF-2.
When '251-insulin was used as the ligand, it was preferentially displaced by insulin. Proinsulin (data not shown) and IGF-2 also cross-react in the brain insulin receptor and are -10-fold less potent than insulin in displacing 1251-insulin from the membrane. IGF-1 and MSA were 100-fold less potent than insulin. reaction studies indicate the existence of separate somatomedin and insulin receptors on human fetal brain plasma membrane.
DISCUSSION The present results demonstrate the presence of somatomedin and insulin receptors in the human fetus. Receptors were present before the end of the first trimester of gestation, suggesting that the human fetus is, already early in gestation, a target for somatomedin and insulin action. The influence of intramuscular prostaglandin administration on the fetus is unknown. However, using this route of administration it is unlikely that prostaglandins are present in sufficient quantities to significantly influence fetal receptors, since only small amounts were present after intraamniotic administration (18, 19) .
Cross-reaction studies using liver and brain plasma In contrast to the brain, the IGF-2 receptor on the liver appears to remain unaltered throughout gestation. The affinity of the liver insulin receptor, however, changes after the fetus has attained 17 cm in length. Thereafter the affinity remains constant and there is an increase in the concentration of insulin receptors. Bernard et al. (28) reported that the transition from fetal to adult forms of thymidine kinase in the human liver occurred at this fetal age. Both these findings indicate a change in liver cell characteristics around the 17th wk of gestational age.
Apart from brain growth, which has been well documented, there is little data available concerning the different periods of cellular growth in the other human fetal organs. Widdowson et al. (9) have examined DNA and protein accumulation in kidneys, heart, liver, and muscle. In all organs cell proliferation occurred rapidly until -25 wk of gestation when the rate of cell formation began to slow and there was growth in terms of cell size. Early in gestation, somatomedin binding was observed in both fetal organs whereas insulin binding tended to increase with increasing maturation. These data suggest that whereas the somatomedins are active from early development, insulin may play a regulatory role later in development. Such a conclusion is in accordance with Hill et al. (30) observations of the growth of fetuses with pancreatic agenesis, where fetal growth appears to have ceased at approximately week 28 of gestation. Similarly, the increased growth of fetuses of diabetic mothers is primarily observed after the same gestational age (31) . Thus, the present findings support the concept that in man, the somatomedins are the primary regulators of the early period of proliferative growth whereas insulin plays a later regulatory role on maturation and hypertrophic growth.
The profound growth retardation observed in Lep-
